Virtus ETF Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-10,558
| Closed | -$719K | – | 488 |
|
|
2022
Q3 | $719K | Buy |
10,558
+152
| +1% | +$8.38K | 0.29% | 101 |
|
|
2022
Q2 | $332K | Sell |
10,406
-4,532
| -30% | -$133K | 0.12% | 260 |
|
|
2022
Q1 | $517K | Hold |
14,938
| – | – | 0.23% | 119 |
|
|
2021
Q4 | $437K | Buy |
14,938
+3,580
| +32% | +$111K | 0.17% | 129 |
|
|
2021
Q3 | $289K | Sell |
11,358
-1,038
| -8% | -$30.5K | 0.13% | 204 |
|
|
2021
Q2 | $434K | Sell |
12,396
-2,258
| -15% | -$88.2K | 0.18% | 185 |
|
|
2021
Q1 | $597K | Buy |
14,654
+400
| +3% | +$18.4K | 0.25% | 124 |
|
|
2020
Q4 | $617K | Buy |
14,254
+4,926
| +53% | +$243K | 0.26% | 103 |
|
|
2020
Q3 | $514K | Buy |
9,328
+786
| +9% | +$50K | 0.27% | 130 |
|
|
2020
Q2 | $539K | Buy |
8,542
+885
| +12% | +$60.7K | 0.26% | 142 |
|
|
2020
Q1 | $391K | Sell |
7,657
-646
| -8% | -$43.3K | 0.16% | 200 |
|
|
2019
Q4 | $660K | Buy |
8,303
+3,626
| +78% | +$215K | 0.11% | 163 |
|
|
2019
Q3 | $227K | Sell |
4,677
-261
| -5% | -$13.6K | 0.05% | 225 |
|
|
2019
Q2 | $260K | Sell |
4,938
-1,404
| -22% | -$80.7K | 0.05% | 266 |
|
|
2019
Q1 | $336K | Sell |
6,342
-752
| -11% | -$37K | 0.71% | 48 |
|
|
2018
Q4 | $291K | Sell |
7,094
-2,959
| -29% | -$111K | 0.05% | 120 |
|
|
2018
Q3 | $382K | Sell |
10,053
-7,196
| -42% | -$319K | 0.04% | 168 |
|
|
2018
Q2 | $780K | Sell |
17,249
-2,082
| -11% | -$94.8K | 0.69% | 43 |
|
|
2018
Q1 | $934K | Buy |
19,331
+9,941
| +106% | +$554K | 0.81% | 53 |
|
|
2017
Q4 | $370K | Sell |
9,390
-2,455
| -21% | -$91.7K | 0.46% | 71 |
|
|
2017
Q3 | $368K | Buy |
11,845
+1,084
| +10% | +$30.5K | 0.05% | 117 |
|
|
2017
Q2 | $294K | Sell |
10,761
-6,624
| -38% | -$197K | 0.04% | 130 |
|
|
2017
Q1 | $641K | Buy |
17,385
+1,666
| +11% | +$42K | 0.11% | 90 |
|
|
2016
Q4 | $227K | Buy |
15,719
+4,009
| +34% | +$70.4K | 0.07% | 163 |
|
|
2016
Q3 | $270K | Hold |
11,710
| – | – | 0.13% | 113 |
|
|
2016
Q2 | $194K | Buy |
11,710
+4,128
| +54% | +$83.3K | 0.14% | 137 |
|
|
2016
Q1 | $120K | Buy |
+7,582
| New | +$135K | 0.17% | 138 |
|
Other funds holding GBT
Virtus ETF Advisers's GBT Position: Q4 2022 in Review
Virtus ETF Advisers sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 10,558 shares — an estimated $719K sold.
Virtus ETF Advisers first reported a position in GBT in Q1 2016 and held it in 27 quarters. The position peaked at $934K in Q1 2018. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Virtus ETF Advisers reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Virtus ETF Advisers sold 10,558 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $719K.
- Virtus ETF Advisers first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 27 quarters.
- Virtus ETF Advisers's Global Blood Therapeutics, Inc. position peaked at $934K in Q1 2018.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.